These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 38828674

  • 21. Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy.
    Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Roobol MJ, Helleman J, van Leenders GJLH.
    Histopathology; 2020 Apr; 76(5):755-762. PubMed ID: 31944367
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Prostatic Ductal Adenocarcinoma Controlled for Tumor Grade, Stage, and Margin Status Does Not Independently Influence the Likelihood of Biochemical Recurrence in Localized Prostate Cancer After Radical Prostatectomy.
    Kryvenko ON, Iakymenko OA, De Lima Guido LP, Bhattu AS, Merhe A, Mouzannar A, Briski LM, Oymagil I, Lugo I, Nemov I, Ritch CR, Kava BR, Punnen S, Jorda M, Parekh DJ, Gonzalgo ML.
    Arch Pathol Lab Med; 2022 Aug 01; 146(8):1012-1017. PubMed ID: 34739539
    [Abstract] [Full Text] [Related]

  • 24. Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma.
    Dong F, Yang P, Wang C, Wu S, Xiao Y, McDougal WS, Young RH, Wu CL.
    Am J Surg Pathol; 2013 Dec 01; 37(12):1855-61. PubMed ID: 24145642
    [Abstract] [Full Text] [Related]

  • 25. Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.
    Miyai K, Divatia MK, Shen SS, Miles BJ, Ayala AG, Ro JY.
    Int J Clin Exp Pathol; 2014 Dec 01; 7(5):2518-26. PubMed ID: 24966964
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Intraductal carcinoma of the prostate in prostate biopsy samples: correlation with aggressive pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer.
    Zhu S, Zhao JG, Chen JR, Liu ZH, Sun GX, Wang ZP, Ni YC, Dai JD, Shen PF, Zeng H.
    Asian J Androl; 2020 Dec 01; 22(5):519-525. PubMed ID: 31710002
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.
    Seyrek N, Hollemans E, Osanto S, Pelger RCM, van der Poel HG, Bekers E, Bangma CH, Rietbergen J, Roobol MJ, Schoots IG, van Leenders GJLH.
    Histopathology; 2022 Feb 01; 80(3):558-565. PubMed ID: 34706119
    [Abstract] [Full Text] [Related]

  • 30. Clinicopathologic Study of Gleason Pattern 5 Prostatic Adenocarcinoma With "Single-cell" Growth Reveals 2 Distinct Types, One With "Plasmacytoid" Features.
    Nguyen JK, Chen YY, Magi-Galluzzi C, McKenney JK.
    Am J Surg Pathol; 2020 Dec 01; 44(12):1635-1642. PubMed ID: 32991340
    [Abstract] [Full Text] [Related]

  • 31. Gleason pattern 4 with cribriform morphology on biopsy is associated with adverse clinicopathological findings in a prospective radical prostatectomy cohort.
    Haffner MC, Salles DC, Gao G, Epstein JI.
    Hum Pathol; 2020 Apr 01; 98():74-80. PubMed ID: 32119879
    [Abstract] [Full Text] [Related]

  • 32. Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy.
    Sandeman K, Eineluoto JT, Pohjonen J, Erickson A, Kilpeläinen TP, Järvinen P, Santti H, Petas A, Matikainen M, Marjasuo S, Kenttämies A, Mirtti T, Rannikko A.
    PLoS One; 2020 Apr 01; 15(7):e0235779. PubMed ID: 32645056
    [Abstract] [Full Text] [Related]

  • 33. Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy.
    Seyrek N, Hollemans E, Andrinopoulou ER, Osanto S, Pelger RCM, van der Poel HG, Bekers E, Remmers S, Schoots IG, van Leenders GJLH.
    Virchows Arch; 2022 Jun 01; 480(6):1149-1157. PubMed ID: 35157140
    [Abstract] [Full Text] [Related]

  • 34. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.
    Walz J, Chun FK, Klein EA, Reuther A, Saad F, Graefen M, Huland H, Karakiewicz PI.
    J Urol; 2009 Feb 01; 181(2):601-7; discussion 607-8. PubMed ID: 19084864
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Evaluation of MSKCC Preprostatectomy nomogram in men who undergo MRI-targeted prostate biopsy prior to radical prostatectomy.
    Glaser ZA, Gordetsky JB, Bae S, Nix JW, Porter KK, Rais-Bahrami S.
    Urol Oncol; 2019 Dec 01; 37(12):970-975. PubMed ID: 31495569
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Prostate Magnetic Resonance Imaging Provides Limited Incremental Value Over the Memorial Sloan Kettering Cancer Center Preradical Prostatectomy Nomogram.
    Weaver JK, Kim EH, Vetter JM, Shetty A, Grubb RL, Strope SA, Andriole GL.
    Urology; 2018 Mar 01; 113():119-128. PubMed ID: 29217354
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.